The search for the genetic factors contributing to Alzheimer disease (AD) has evolved
tremendously throughout the years. It started from the discovery of fully penetrant mutations …

Age, apolipoprotein E ε4 (APOE) and chromosomal sex are well-established risk factors for
late-onset Alzheimer's disease (LOAD; AD). Over 60% of persons with AD harbor at least …

Alzheimer's disease (AD) is a progressive neurodegenerative disease that represents the
most common form of dementia among the elderly. Despite the fact that AD was studied for …

The APOE gene, encoding apolipoprotein E, is the primary genetic risk factor for late-onset
Alzheimer's disease (AD). Apolipoprotein E ɛ4 allele (APOE4) carriers have alterations in …

Abstract The methodology of Genome-Wide Association Screening (GWAS) has been
applied for more than a decade. Translation to clinical utility has been limited, especially in …

The practical pharmacogenetics of Alzheimer's disease (AD) is circumscribed to
acetylcholinesterase inhibitors (AChEIs) and memantine. However, pharmacogenetic …

Abstract The Translocase of Outer Mitochondrial Membrane 40 Homolog and Apolipoprotein
E (TOMM40-APOE) locus has been associated with a number of age-related phenotypes in …

Type II diabetes mellitus (DM) increases risk for cognitive decline and is associated with
brain atrophy in older demented and non-demented individuals. We investigated (1) the …

Neurodegenerative diseases comprise an array of progressive neurological disorders all
characterized by the selective death of neurons in the central nervous system. Although, rare …

Clinical trials for Alzheimer's disease are now focusing on the earliest stages of the disease
with the goal of delaying dementia onset. There is great utility in using genetic variants to …